Literature DB >> 1974297

Lipid peroxidation effects of a novel iron compound, ferric maltol. A comparison with ferrous sulphate.

R K Singh1, M A Barrand.   

Abstract

Lipid peroxidation effects of ferric maltol have been compared with those of ferrous sulphate both in lecithin liposomes and in brush border and mitochondrial membranes prepared from rat small intestine. Ferrous sulphate, but not ferric maltol, initiated peroxidation in liposomes as measured by conjugated diene production, but, with 500 microM ascorbic acid present, both caused intense peroxidation which was inhibitable by N2, tocopherol, maltol and ferrous chelators, but not by OH or H2O2 scavengers. The rate of peroxidation increased with ferrous sulphate concentration up to 100 microM but was independent of ferric maltol concentration between 5-500 microM. Material eluted from rat small intestine contained a reducing factor, similar in size to ascorbic acid, capable of generating ferrous ions from ferric maltol and initiating peroxidation. Peroxidation in mitochondrial membranes appeared unaffected by addition of iron whilst that in brush border membranes was detectable only in the presence of iron. At iron concentrations of 100 microM and above ferric maltol produced less liposomal peroxidation than ferrous sulphate. Maltol itself may delay recycling of Fe3+ to Fe2+. Thus ferric maltol could provide a less toxic alternative to ferrous salts in the oral treatment of iron-deficiency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974297     DOI: 10.1111/j.2042-7158.1990.tb05407.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

1.  Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat.

Authors:  M A Barrand; B A Callingham; P Dobbin; R C Hider
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

2.  Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.

Authors:  Christoph Gasche; Tariq Ahmad; Zsolt Tulassay; Daniel C Baumgart; Bernd Bokemeyer; Carsten Büning; Stefanie Howaldt; Andreas Stallmach
Journal:  Inflamm Bowel Dis       Date:  2015-03       Impact factor: 5.325

Review 3.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.